HIV-1 transmitted drug resistance in latin America and the Caribbean: What do we know?

AIDS Reviews

Volumn 14, Issue 4, 2012, Pages 256-267

  Pineda Peña, Andrea Clemencia ^a,b   Bello, Diana Carolina ^a   Sussmann, Otto ^a   Vandamme, Anne Mieke ^b,c   Vercauteren, Jurgen ^b   Van Laethem, Kristel ^b,d   Gómez López, Arley ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Caribbean; Drug resistance; Genotype; HIV 1; Latin America; Naive

Indexed keywords

NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ZIDOVUDINE;

BLOOD TOXICITY; BRAZIL; CD4 LYMPHOCYTE COUNT; CENTRAL AMERICA; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEXICO; PREVALENCE; RASH; REVIEW; RISK FACTOR; SOCIOECONOMICS; SOUTH AND CENTRAL AMERICA; VENEZUELA; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CARIBBEAN REGION; DRUG RESISTANCE, VIRAL; FEMALE; GUIDELINES AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; LATIN AMERICA; MALE; MUTATION, MISSENSE; PREVALENCE;

EID: 84871658671     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Erice A, Mayers D, Strike D, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993;328:1163-5. (Pubitemid 23105754)
2. Jayaraman G, Archibald C, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr. 2006;42:86-90. (Pubitemid 43947951)
3. Weinstock H, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-80. (Pubitemid 38757188)
4. Vercauteren J, Wensing A, van de Vijver D, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200:1503-8.
5. SPREAD. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22:625-35.
6. Vandamme A, Camacho R, Ceccherini-Silberstein F, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011;13:77-108.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf.; 2011;1-167.
8. Wittkop L, Gunthard H, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-71.
9. UNAIDS-WHO. GLOBAL REPORT: UNAIDS Report on the global AIDS epidemic. Geneva; 2010.
10. Chequer P, Cuchi P, Mazin R, Garcia Calleja J. Access to antiretroviral treatment in Latin American countries and the Caribbean. AIDS. 2002;16(Suppl 3):S50-7. (Pubitemid 36177344)
11. Teixeira P, Vitoria M, Barcarolo J. Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS. 2004;18(Suppl 3):S5-7. (Pubitemid 39037452)
12. UNAIDS-WHO. GLOBAL HIV/AIDS RESPONSE. Epidemic update and health sector progress towards Universal Access. Geneva, Switzerland; 2011.
13. Ravasi G, Pérez-Rosales M, Mejía Cruz V, et al. WHO HIV drug resistance early warning indicators as treatment program monitoring and evaluation tool in Central American countries. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy; 2011. [Abstract TUAD0105].
14. Jack N, Ravasi G, Schrooten W, Del Riego A, Hirnschall G. Implementing HIV drug resistance early warning indicators in the Caribbean. In: XVIII International AIDS Conference, Vienna, Austria; 2010. [Abstract THPE0354].
15. Jordan M, Kelley K, Saadani-Hassani A, Obeng-Aduasare Y, Bertagnolio S. Monitoring ART Clinic and Program Performance Using World Health Organization HIV Drug Resistance Early Warning Indicators. 18th CROI; Boston, USA; 2011.
16. Bennett D, Jordan M, Bertagnolio S, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis. 2012;54(Suppl 4):S280-9.
17. Tuboi S, Schechter M, McGowan C, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009;51:615-23.
18. Crabtree-Ramírez B, Caro-Vega Y, Shepherd B, et al. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: Late testers and late presenters. PLoS One. 2011;6:e20272.
19. Bennett D, Bertagnolio S, Sutherland D, Gilks C. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1-13. (Pubitemid 352019085)
20. Bennett D, Myatt M, Bertagnolio S, Sutherland D, Gilks C. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(Suppl 2):25-36. (Pubitemid 352019087)
21. Bennett D, Camacho R, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
22. Barreto C, Nishyia A, Araujo L, Ferreira J, Busch M, Sabino E. Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr. 2006;41:338-41.
23. Brindeiro R, Vanderborght B, Caride E, et al. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob Agents Chemother. 1999;43:1674-80. (Pubitemid 29331246)
24. Sa-Ferreira J, Brindeiro P, Chequer-Fernandez S, Tanuri A, Morgado M. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naive Brazilian blood donors. Transfusion. 2007;47:97-102. (Pubitemid 46006315)
25. Pando M, Eyzaguirre L, Carrion G, et al. High genetic variability of HIV-1 in female sex workers from Argentina. Retrovirology. 2007;4:58.
26. Maia Teixeira S, Bastos F, Hacker M, Guimaraes M, Morgado M. Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol. 2006;78:764-9.
27. Eyzaguirre L, Brouwer K, Nadai Y, et al. First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border. AIDS Res Hum Retroviruses. 2007;23:331-4. (Pubitemid 46418348)
28. Janssen R, Satten G, Stramer S, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-8. (Pubitemid 28414995)
29. Arruda E, Simoes L, Sucupira C, et al. Short communication: intermediate prevalence of HIV type 1 primary antiretroviral resistance in Ceara State, Northeast Brazil. AIDS Res Hum Retroviruses. 2011;27:153-6.
30. Brigido L, Nunes C, Oliveira C, et al. HIV type 1 subtype C and CB Pol recombinants prevail at the cities with the highest AIDS prevalence rate in Brazil. AIDS Res Hum Retroviruses. 2007;23:1579-86.
31. Dilernia D, Lourtau L, Gomez A, et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS. 2007;21:1355-60. (Pubitemid 46883491)
32. Lama J, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr. 2006;42:501-5. (Pubitemid 44050901)
33. Pando M, Gomez-Carrillo M, Vignoles M, et al. Incidence of HIV type 1 infection, antiretroviral drug resistance, and molecular characterization in newly diagnosed individuals in Argentina: A Global Fund Project. AIDS Res Hum Retroviruses. 2011;27:17-23.
34. Sucupira M, Caseiro M, Alves K, et al. High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. AIDS Patient Care STDS. 2007;21:116-28. (Pubitemid 46394455)
35. Varella R, Ferreira S, de Castro M, Zalis M, Tavares M. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil. J Med Virol. 2007;79:1033-9. (Pubitemid 47015400)
36. Ferreira J, Thomaz M, Rodrigues R, et al. Molecular characterisation of newly identified HIV-1 infections in Curitiba, Brazil: preponderance of clade C among males with recent infections. Mem Inst Oswaldo Cruz. 2008;103:800-8.
37. Acevedo W, Gallardo A, Galaz J, Afani A, Cortes E. [Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)]. Rev Med Chil. 2007;135:1406-13.
38. Afani A, Beltran C, Maria Gallardo A, Roessler P, Acevedo W, Vasquez P. [Prevalence of primary antiretroviral resistance among HIV infected patients in Chile]. Rev Med Chil. 2010;138:669-76.
39. Inocencio L, Pereira A, Sucupira M, et al. Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc. 2009;12:20.
40. Kijak G, Pampuro S, Gomez Carrillo M, et al. Resistance Profiles to Antiretroviral Drugs in HIV-1-Naive Patients. In: 7th CROI; San Francisco, USA; 2000.
41. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr. 2006;42:506-10. (Pubitemid 44050902)
42. Arreseigor T, Valle M, Rimoldi I. Primary drug resistance in newly diagnosed HIV-1 infected individuals in Buenos Aires province. In: XVIII IAC: Vienna, Austria; 2010. [Abstract CDC0464].
43. De Moraes Soares C, Vergara T, Sucupira M, et al. Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating ART in Brazil: A surveillance using dried blood spots. In: 18th CROI. Boston, USA; 2011.
44. Murillo W, Paz-Bailey G, Morales S, et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol. 2010;49:239-44.
45. Avila-Rios S, Garcia-Morales C, Garrido-Rodríguez D, et al. National Prevalence and Trends of HIV Transmitted Drug Resistance in Mexico. In: 18th CROI. Boston, USA; 2011.
46. Castillo J, Comegna M, Quijada W, et al. Surveillance of HIV type 1 drug resistance among naive patients from Venezuela. AIDS Res Hum Retroviruses. 2009;25:1329-33.
47. Cardoso L, Queiroz B, Stefani M. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil. J Clin Virol. 2009;46:134-9.
48. Carvalho B, Cardoso LP, Damasceno S, Stefani M. Moderate prevalence of transmitted drug resistance and interiorization of HIV Type 1 Subtype C in the Inland North State of Tocantins, Brazil. AIDS Res Hum Retroviruses. 2011;271081-7.
49. Medeiros M, Arruda E, Guerrant R, et al. Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in northeast Brazil. Braz J Infect Dis. 2007;11:390-4. (Pubitemid 47520438)
50. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21:3797-800. (Pubitemid 41535530)
51. UNAIDS-WHO. Progress on Global Access to HIV Antiretroviral Therapy: A Report on "3 by 5" and Beyond. Geneva, Switzerland: WHO; 2006.
52. Gittens M, Roth W, Roach T, et al. The molecular epidemiology and drug resistance determination of HIV type 1 subtype B infection in Barbados. AIDS Res Hum Retroviruses. 2003;19:313-19. (Pubitemid 36458224)
53. Perez L, Alvarez L, Carmona R, et al. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res Hum Retroviruses. 2007;23:407-14. (Pubitemid 46608561)
54. Ruibal-Brunet I, Cuevas M, Diaz-Torres H, et al. Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba. Rev Panam Salud Publica. 2001;10:174-80. (Pubitemid 32979561)
55. Vaughan H, Cane P, Pillay D, Tedder R. Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. AIDS Res Hum Retroviruses. 2003;19:929-32. (Pubitemid 37338921)
56. Ahumada-Ruiz S, Flores-Figueroa D, Toala-Gonzalez I, Thomson M. Analysis of HIV-1 pol sequences from Panama: identification of phylogenetic clusters within subtype B and detection of antiretroviral drug resistance mutations. Infect Genet Evol. 2009;9:933-40.
57. Castillo J, Mendoza Y, Martinez A, et al. Prevalence of transmitted antiretroviral drug resistance in recently HIV infected individuals and newborns from Panama. XVIII IAC, Vienna, Austria; 2010. [Abstract THPE0358].
58. Lloyd B, O'Connell R, Michael N, et al. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses. 2008;24:529-35. (Pubitemid 351571035)
59. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med. 2005;6:403-9. (Pubitemid 41723308)
60. Valle-Bahena O, Ramos-Jimenez J, Ortiz-Lopez R, et al. Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients. Arch Med Res. 2006;37:1022-7. (Pubitemid 44540239)
61. Bouchard M, Masquelier B, Moreno M, et al. HIV type 1 drug resistance among naive patients from Venezuela. AIDS Res Hum Retroviruses. 2007;23:482-5. (Pubitemid 46608570)
62. Delgado E, Leon-Ponte M, Villahermosa M, et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res Hum Retroviruses. 2001;17:753-8. (Pubitemid 32692413)
63. Hernandez M, Matos D, Rodrigues R, Cedeño C, Rivera A. Resumen del estudio sobre perfil del paciente con VIH y adherencia al tratamiento antirretroviral en Venezuela. Venezuela: Ministerio del Poder Popular para la Salud; 2008.
64. DiazGranados C, Mantilla M, Lenis W. Antiretroviral drug resistance in HIV-infected patients in Colombia. Int J Infect Dis. 2010;14:e298-303.
65. Guanira J, Lama J, Montoya O, et al. HIV drug resistance in the Andean Region: a look after the universal access to HAART in the Andean region. In: 18th International HIV Drug Resistance Workshop Basic Principles &Clinical Implications; Fort Myers, USA. Antivir Ther. 2009;14(Suppl 1):A174. [Abstract 151 2009].
66. Dumans A, Soares M, Pieniazek D, et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother. 2002;46:3075-9.
67. Brindeiro R, Diaz R, Sabino E, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS. 2003;17:1063-9. (Pubitemid 36549719)
68. Soares M, Brindeiro R, Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS. 2004;18(Suppl 3):S9-13.
69. Soares E, Santos R, Pellegrini J, Sprinz E, Tanuri A, Soares M. Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr. 2003;34:520-6. (Pubitemid 37500478)
70. Eyer-Silva W, Morgado M. A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. Mem Inst Oswaldo Cruz. 2005;100:869-73. (Pubitemid 43213814)
71. Lacerda H, Medeiros L, Cavalcanti A, Ximenes R, Albuquerque M. Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1. Mem Inst Oswaldo Cruz. 2007;102:693-9. (Pubitemid 350139056)
72. Gonsalez C, Alcalde R, Nishiya A, et al. Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res. 2007;129:87-90. (Pubitemid 47595356)
73. Pires I, Soares M, Speranza F, et al. Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol. 2004;42:426-30. (Pubitemid 38082763)
74. Rodrigues R, Scherer L, Oliveira C, et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res. 2006;116:201-7. (Pubitemid 43221733)
75. Sprinz E, Netto E, Patelli M, et al. Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil. AIDS Res Hum Retroviruses. 2009;25:861-7.
76. Kijak G, Pampuro S, Avila M, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther. 2001;6:71-7. (Pubitemid 33704484)
77. Rubio A, Pando M, Dilernia D, Trinchero J, Rovner N, Salomon H. Primary resistance in newly diagnosed HIV-1 infected drug-naïve individuals from Buenos Aires, Argentina: a two-period comparison. In: 18th International HIV Drug Resistance Workshop Basic Principles & Clinical Implications; Fort Myers, Florida. Antivir Ther. 2009;14(Suppl 1):A175. [Abstract 152].
78. Petroni A, Deluchi G, Lopardo G, et al. Update on transmission of HIV resistance to drug-naive patients in Argentina. In: International HIV &Hepatitis Virus Drug Resistance Workshop and Curative Strategies; Dubrovnik, Croatia. Antivir Ther. 2010;15(Suppl 2): A179. [Abstract 141].
79. Rios M, Delgado E, Perez-Alvarez L, et al. Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol. 2007;79:647-56. (Pubitemid 46709357)
80. Frentz D, Van de Vijver D, Wensing A, Bowles E, Boucher C. Worldwide comparison of mutational patterns in studies on transmission of drug resistant HIV-1 across the World. Update on WATCH. In: 6th European HIV Drug Resistance Workshop. Budapest, Hungary; 2008.
81. Hamers R, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit T, Schuurman R. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008;13:625-39.
82. Shekelle P, Maglione M, Geotz M, et al. Antiretroviral (ARV) drug resistance in the developing world. Evid Rep Technol Assess (Full Rep). 2007;156:1-74.
83. Afani A, Ayala M, Meyer A, Cabrera R, Acevedo W. [Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile]. Rev Med Chil. 2005;133:295-301.
84. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005;40:505-11. (Pubitemid 41669152)
85. Booth C, Geretti A. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047-56. (Pubitemid 47073314)
86. Little S, Smith D. HIV treatment decisions and transmitted drug resistance. Clin Infect Dis. 2005;41:233-5. (Pubitemid 40962505)
87. Bon I, Gibellini D, Borderi M, et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol. 2007;38:313-20. (Pubitemid 46413996)
88. Beyrer C, Baral S, Walker D, Wirtz A, Johns B, Sifakis F. The expanding epidemics of HIV type 1 among men who have sex with men in low- and middle-income countries: diversity and consistency. Epidemiol Rev. 2010;32:137-51.
89. Bermudez E, Kerr L, Pinho A, et al. Antiretroviral drug resistance in men who have sex with men in Brazil. In: XVIII IAC. Vienna, Austria; 2010. [Abstract FRLBC103].
90. ONUSIDA-Republica Bolivariana de Venezuela. Informe Anual 2009. Fortaleciendo la Respuesta Nacional y Conjunta al VIH y sida. Caracas, Venezuela; 2009.
91. Soares E, Martinez A, Souza T, et al. HIV-1 subtype C dissemination in southern Brazil. AIDS. 2005;19(Suppl 4):S81-6. (Pubitemid 41668992)
92. de Medeiros L, Lacerda H, Cavalcanti A, de Albuquerque M. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2006;101:845-9. (Pubitemid 46131332)
93. Eyer-Silva W, Couto-Fernandez J, Silva-de-Jesus C, Morgado M. Prevalence of HIV type 1 drug resistance mutations in treatment-naive and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities. Mem Inst Oswaldo Cruz. 2008;103:143-9. (Pubitemid 351535008)
94. de Sa-Filho D, Ambar R, Duarte N, et al. HIV type 1 diversity from newly diagnosed patients in Santos metropolitan area/Brazil. AIDS Res Hum Retroviruses. 2009;25:925-9.
95. Rangel H, Garzaro D, Torres J, et al. Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Mem Inst Oswaldo Cruz. 2009;104:522-5.
96. Fuentes-Romero L, Rodriguez-Diaz R, Viveros-Rogel M, et al. Genotypic HIV Drug resistance among newly diagnosed, never treated persons in Mexico. In: 13th International HIV Drug Resistance Workshop; Canary Islands, Spain. Antivir Ther. 2004;9:S111.
97. Garrido-Rodríguez D, Avila-Rios S, Vázquez-Pérez J, et al. Molecular epidemiology of HIV in Mexico: a clade B-dominated epidemic with low prevalence of primary drug resistance. In: XVII IAC. Mexico City, Mexico; 2008. [Abstract TUPE0019].
98. Escoto-Delgadillo M, López-Lomelí M, Gonzáles- Morales L, Demi-Castellanos E, Vásquez-Valls E. Frequency of primary mutations to antiretrovirals in Mexican population In: XIV IAC. Barcelona, Spain; 2002. [Abstract B10411].
99. Andrade-Villanueva J, Amador-Lara F, Ortiz-Macias X, Mora-Jimenez E. Primary HIV Drug Resitance in Referral HIV Unit in Mexico. In: 42nd Annual Meeting of IDSA. USA; 2004. [Abstract 910].
100. Rodriguez-Diaz R, Fuentes-Romero L, Viveros-Rogel M, et al. Does Mexico need to use genotypic resistance testing before starting treatment in naive patients with recent HIV diagnosis? In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Bangkok, Thailand; 2007. [Abstract CDB235].
101. Silva F, Andrade J, Espinosa-Aguilar L, et al. Primary genotypic resistance in chronically infected patients screened for clinical trials in Mexico. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract TUPE0032].
102. Patterson P, Krolewiecki A, Vázquez L, et al. Frequency distribution of mutations in HIV-1 subtypes B and BF in treatment-naive patients from Argentina. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract TUPE0021].
103. Parenti P, David D, Casiro A, et al. Prevalence of primary drug resistance in HIV-1 infected patients in Argentina. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract MOPDA206].
104. Argel M, Gonzalez P, Esposto A, et al. HIV-1 Genomic characterization from naive patients in La Plata City, province of Buenos Aires, Argentina. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract CDA0033].
105. Dias-Tavares M, Brandão-Varella R, Baía-Fereira S, Braga de Castro M, Correa-Malta F, Schechter M. Large scale use of antiretroviral drugs is not associated with a high prevalence of genotypic resistance mutations in treatment-naive HIV-1 infected individuals in Rio de Janeiro, Brazil. In: 2nd IAS Conference on HIV Pathogenesis and Treatment: Paris, France; 2003. [Abstract 778].
106. Velasco de Castro C, Grinsztejn V, Veloso V, et al. HIV-1 subtypes and antiretroviral drug resistance mutations among recent (RS) and long-term seroconverters (LTS) from VCTs of Rio de Janeiro state, Brazil. In: XVI IAC: Toronto, Canada; 2006. [Abstract MOPE0385].
107. Waléria-Aleixo A, Tanuri A, Cleto S, Greco D. Mutations related to primary resistance to antiretrovirals among newly HIV-1 infected individuals in Belo Horizonte-Brazil. In: 2nd IAS Conference on HIV Pathogenesis and Treatment: Paris, France; 2003. [Abstract 242].
108. Rodrigues R, Oliveira C, Custodio R, et al. Diversity in Sáo Paulo: low ARV resistance in HIV incident infections. In: XV IAC: Bangkok, Thailand; 2004. [Abstract MoPeC3426].
109. Couto-Fernandez J, Brindeiro R, Inocencio L, et al. Time trends in primary resistance to HIV drugs in the chronically infected ARV-naïve population in Rio de Janeiro, Brazil. In: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies; Dubrovnik, Croatia: Antivir Ther. 2010;15(Suppl 1):A152.
110. Gagliani L, Alkmim Maia W, Caseiro M, Sá-Filho D, Teixeira C, Diaz R. Primary drug antiretroviral resistance and HIV-1 subtype among antiretroviral-naïve patients immediately before starting HAART in Santos, Brazil. XVII IAC: Mexico City, Mexico; 2008. [Abstract TUPE0025].
111. Sucupira M, Sanabani S, Côrtes R, et al. Primary antiretroviral resistance among individuals with recent HIV infection in the city of São Paulo, Brazil: use of full-length genome sequencing to evaluate six antiretroviral classes. In: 18th International HIV Drug Resistance Workshop Basic Principles & Clinical Implications; Fort Myers, USA. Antivir Ther. 2009;14(Suppl 1):A172. [Abstract 149].
112. Rodrigues R, Knoll R, Nunes C, et al. Low primary HIV drug resistance mutations in South Brazil. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract TUPE0027].
113. Sousa T, Dumans A, Kurck I, Moreira de Sá C, Sion F, Soares M. Increasing in primary antiretroviral resistance among untreated HIV-infected individuals in Rio de Janeiro city, Brazil. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Bangkok, Thailand; 2007. [Abstract CDB234].
114. Ambar R, Duarte N, Thome M, et al. HIV-1 pol gene diversity and antiretroviral drug resistance mutations in drug naïve patients from Santos metropolitan area, Brazil. In: XVII IAC: Mexico City, Mexico; 2008. [Abstract MOPDA203].
115. Diaz R, De Souza R, Sucupira M, et al. Lower prevalence of primary antiretroviral resistance among clade C infected individuals as compared to clade B in South Brazil's emerging clade C HIV-1 epidemic In: XVII IAC: Mexico City, Mexico; 2008. [Abstract TUAA02].